Ditte M Kirkegaard-Klitbo1, Niels Mejer, Troels B Knudsen, Holger J Møller, Søren K Moestrup, Susanne D Poulsen, Gitte Kronborg, Thomas Benfield. 1. aDepartment of Infectious Diseases, Hvidovre Hospital bDepartment of Infectious Diseases, Rigshospitalet cDepartment of Pulmonary and Infectious Diseases, Hillerød Hospital, University of Copenhagen, Copenhagen dDepartment of Clinical Biochemistry, Aarhus University Hospital, Aarhus eDepartment of Molecular Medicine, University of Southern Denmark, Odense fDepartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Abstract
OBJECTIVE: To examine if monocyte and macrophage activity may be on the mechanistic pathway to non-AIDS comorbidity by investigating the associations between plasma-soluble CD163 (sCD163) and incident non-AIDS comorbidities in well treated HIV-infected individuals. DESIGN: Prospective single-center cohort study. METHODS: Plasma sCD163 was quantified by ELISA technique at study entry in 2004/2005, and non-AIDS comorbidity was identified by International Classification of Disease Tenth revision diagnosis codes and registry linkage in 2015. Associations between sCD163 and incident comorbidity was examined using multivariable Cox proportional hazards models adjusted for pertinent covariates. RESULTS: In HIV-1-infected individuals (n = 799), the highest quartile of plasma sCD163 was associated with incident chronic lung disease [adjusted hazard ratio (aHR), 3.2; 95% confidence interval (CI): 1.34; 7.46] and incident chronic kidney disease (aHR, 10.94; 95% CI: 2.32; 51.35), when compared with lowest quartiles. Further, (every 1 mg) increase in plasma sCD163 was positively correlated with incident liver disease (aHR, 1.12; 95% CI: 1.05; 1.19). The sCD163 level was not associated with incident cancer, cardiovascular disease or diabetes mellitus. CONCLUSION: sCD163 was independently associated with incident chronic kidney disease, chronic lung disease and liver disease in treated HIV-1-infected individuals, suggesting that monocyte/macrophage activation may be involved in the pathogenesis of non-AIDS comorbidity and a potential target for therapeutic intervention.
OBJECTIVE: To examine if monocyte and macrophage activity may be on the mechanistic pathway to non-AIDS comorbidity by investigating the associations between plasma-soluble CD163 (sCD163) and incident non-AIDS comorbidities in well treated HIV-infected individuals. DESIGN: Prospective single-center cohort study. METHODS: Plasma sCD163 was quantified by ELISA technique at study entry in 2004/2005, and non-AIDS comorbidity was identified by International Classification of Disease Tenth revision diagnosis codes and registry linkage in 2015. Associations between sCD163 and incident comorbidity was examined using multivariable Cox proportional hazards models adjusted for pertinent covariates. RESULTS: In HIV-1-infected individuals (n = 799), the highest quartile of plasma sCD163 was associated with incident chronic lung disease [adjusted hazard ratio (aHR), 3.2; 95% confidence interval (CI): 1.34; 7.46] and incident chronic kidney disease (aHR, 10.94; 95% CI: 2.32; 51.35), when compared with lowest quartiles. Further, (every 1 mg) increase in plasma sCD163 was positively correlated with incident liver disease (aHR, 1.12; 95% CI: 1.05; 1.19). The sCD163 level was not associated with incident cancer, cardiovascular disease or diabetes mellitus. CONCLUSION: sCD163 was independently associated with incident chronic kidney disease, chronic lung disease and liver disease in treated HIV-1-infected individuals, suggesting that monocyte/macrophage activation may be involved in the pathogenesis of non-AIDS comorbidity and a potential target for therapeutic intervention.
Authors: Lene Ryom; Jens D Lundgren; Peter Reiss; Mike Ross; Ole Kirk; Christophe A Fux; Phillipe Morlat; Eric Fontas; Colette Smith; Stephane De Wit; Antonella d'Arminio Monforte; Wafaa El Sadr; Camilla Hatleberg; Andrew Phillips; Caroline Sabin; Matthew Law; Amanda Mocroft Journal: J Infect Dis Date: 2021-02-24 Impact factor: 5.226
Authors: David M MacDonald; Alexander D Zanotto; Gary Collins; Jason V Baker; Marcin Czarnecki; Eliana Loiza; Daniel E Nixon; Vasileios Papastamopoulos; Chris H Wendt; Robin Wood; Ken M Kunisaki Journal: AIDS Date: 2019-03-15 Impact factor: 4.177
Authors: Crystal M North; Daniel Muyanja; Bernard Kakuhikire; Alexander C Tsai; Russell P Tracy; Peter W Hunt; Douglas S Kwon; David C Christiani; Samson Okello; Mark J Siedner Journal: J Acquir Immune Defic Syndr Date: 2018-08-15 Impact factor: 3.771
Authors: Amanda K Jan; Julia V Moore; Richard J Wang; Maggie Mcging; Carly K Farr; Daniela Moisi; Marlena Hartman-Filson; Robert Kerruish; Diane Jeon; Eula Lewis; Kristina Crothers; Michael M Lederman; Peter W Hunt; Laurence Huang Journal: AIDS Date: 2021-06-01 Impact factor: 4.632
Authors: Audrey L French; Dara Grennan; Elizabeth Daubert; Eric C Seaberg; Marion Peters; Michael Augenbraun; Margaret Fischl; Seble Kassaye; Ricardo Franco; Mark Kuniholm; Adaora A Adimora; Kimberly Workowski; Kathleen M Weber Journal: AIDS Date: 2021-07-15 Impact factor: 4.632
Authors: Samuel R Schnittman; Helen Byakwaga; Yap Boum; Jerome Kabakyenga; Lynn T Matthews; Tricia H Burdo; Yong Huang; Russell P Tracy; Jessica E Haberer; Annet Kembabazi; Angela Kaida; Daniela Moisi; Michael M Lederman; David R Bangsberg; Jeffrey N Martin; Peter W Hunt Journal: Open Forum Infect Dis Date: 2021-05-17 Impact factor: 3.835